Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05580003 · ClinicalTrials.gov registry record · Phase 1
A Study to Learn Safety and Blood Levels of PF-07817883 in Healthy People
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 94
- Enrollment target
NCT05580003 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 94 participants.
The verdict
NCT05580003, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 94 participants
- Enrollment target
Study Summary
The purpose of this clinical trial is to learn if the study medicine (called PF-07817883) is safe and how it goes in and out of the body in healthy people. PF-07817883 is for the potential treatment of COVID-19. Participants will take PF-07817883 by mouth up to 2 times a day. This study may also evaluate how much PF-07817883 gets into the body when taken as pill. We may study if people's diets can affect this study medicine. We may also examine how PF-07817883 is processed and removed by the human body. Finally, we may look into if PF-07817883 has potential to interact with midazolam.
Interventions
- DRUG Placebo
- DRUG Midazolam
- DRUG Moxifloxacin
- DRUG PF-07817883
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2022-10-17 |
| Est. Completion | 2023-09-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05580003
The ClinicalTrials.gov registry entry for NCT05580003 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 94 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT05580003 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05580003 about?
NCT05580003 is a clinical study titled "A Study to Learn Safety and Blood Levels of PF-07817883 in Healthy People". The purpose of this clinical trial is to learn if the study medicine (called PF-07817883) is safe and how it goes in and out of the body in healthy people. PF-07817883 is for the potential treatment of COVID-19. Participants will take PF-07817883 by mouth up to 2 times a day. This study may also eva...
What is the current status of trial NCT05580003?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 94 participants. The study started on 2022-10-17. Estimated completion is 2023-09-15.
What interventions are being tested in trial NCT05580003?
The interventions under investigation include: Placebo (DRUG), Midazolam (DRUG), Moxifloxacin (DRUG), PF-07817883 (DRUG).
Who is sponsoring clinical trial NCT05580003?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.